Israel-based medical technology company Insightec has signed a definitive agreement for funding of about $150m to support continued research to evaluate focused ultrasound for the treatment of certain movement disorders.
Series F financing at a post-money valuation of $1.3bn is led by Koch, Inc.’ subsidiary Koch Disruptive Technologies (KDT), which has committed to invest $100m at an initial closing to follow shareholder approval.
This is the second direct investment by the company in Insightec.
In 2016, Insightec obtained the US Food and Drug Administration (FDA) approval for its Exablate Neuro system for the treatment of certain movement disorders in patients with essential tremor and tremor-dominant Parkinson’s disease.
Exablate incisionless neurosurgery platform is the first MR-guided ultrasound device.
